Animal Toxicity of Hairpin Pyrrole-Imidazole Polyamides Varies with the Turn Unit
Abstract
A hairpin pyrrole-imidazole polyamide (1) targeted to the androgen receptor consensus half-site was found to exert antitumor effects against prostate cancer xenografts. A previous animal study showed that 1, which has a chiral amine at the α-position of the γ-aminobutyric acid turn (γ-turn), did not exhibit toxicity at doses less than 10 mg/kg. In the same study, a polyamide with an acetamide at the β-position of the γ-turn resulted in animal morbidity at 2.3 mg/kg. To identify structural motifs that cause animal toxicity, we synthesized polyamides 1–4 with variations at the α- and β-positions in the γ-turn. Weight loss, histopathology, and serum chemistry were analyzed in mice post-treatment. While serum concentration was similar for all four polyamides after injection, dose-limiting liver toxicity was only observed for three polyamides. Polyamide 3, with an α-acetamide, caused no significant evidence of rodent toxicity and retains activity against LNCaP xenografts.
Additional Information
© 2013 American Chemical Society. ACS AuthorChoice. Received: July 19, 2013. Publication Date (Web): September 9, 2013. This work was supported in part by the National Institutes of Health (Grant GM27681), Sanofi, and the Prostate Cancer Foundation. The authors thank Janet Baer and Gwen E. Williams for helpful discussions. The authors also thank the IDEXX-RADIL team for assistance with serum analysis. Author Contributions: F.Y. and N.G.N contributed equally. F.Y., N.G.N., and P.B.D. designed the experiments. F.Y. and N.G.N. conducted animal experiments. B.C.L. and J.W. synthesized the compounds. J.O.S. conducted liver uptake experiments. S.R.H. performed histopathology analysis. F.Y. and N.G.N. performed cytotoxicity, comet, and ELISA experiments. F.Y. conducted confocal experiments. N.G.N. conducted RT-qPCR experimnts. J.L.M. ran thermal denaturation experiments. F.Y., N.G.N., J.O.S., S.R.H., J.L.M., and P.B.D. analyzed data. F.Y., N.G.N., and P.B.D. wrote the paper. The authors declare no competing financial interest.Attached Files
Published - jm401100s.pdf
Supplemental Material - jm401100s_si_001.pdf
Files
Name | Size | Download all |
---|---|---|
md5:fd968a214eae3cf8a16a30d641da8191
|
1.8 MB | Preview Download |
md5:fac80c6ed8b05ea34f3b922d883d1715
|
4.5 MB | Preview Download |
Additional details
- PMCID
- PMC3788622
- Eprint ID
- 43976
- Resolver ID
- CaltechAUTHORS:20140225-100138273
- NIH
- GM-27681
- Sanofi
- Prostate Cancer Foundation
- Created
-
2014-02-25Created from EPrint's datestamp field
- Updated
-
2021-11-10Created from EPrint's last_modified field